BI, Lilly go simple in new SGLT med-ed effort

BI, Lilly go simple in new SGLT med-ed effort


Boehringer Ingelheim and Eli Lilly rolled out a pre-launch SGLT campaign that breaks ranks with branding for J&J's SGLT2 inhibitor Invokana.

BMS, Abbott HCV pill data suggest competition for Gilead


Abbott and BMS peeled back the curtain on some impressive clinical trial results, suggesting that Gilead may have some competition in the sprint for an all-oral anti-HCV treatment.

Boehringer Ingelheim prepares to launch oncology franchise


Boehringer Ingelheim has long been associated with treatments for stroke prevention, COPD and HIV/AIDS, but not cancer. That's about to change, if a cornucopia of 13 abstracts presented at the European Society for Medical Oncology (ESMO) is any evidence.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.